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Pretreatment of human embryonic pituitary tumour cells (Flow 9000) with pertussis toxin significantly re- 
duced carbachol-mediated inhibition of isoprenaline and prostaglandin EZ stimulation of cyclic AMP for- 
mation. This is in accord with an action on the inhibitory Gi-protein by pertussis toxin. In contrast, pertussis 
toxin-pretreatment had no effect on either muscarinic agonist or GTP[S] (a non-hydrolysable GTP ana- 
logue) stimulation of [3H]inositol phosphate production in intact and permeabilized PH]inositol-prelabelled 
Flow 9000 cells, respectively. These results suggest that muscarinic receptors are linked to the inhibition 
of adenylate cyclase and the stimulation of phosphoinositidase C via two different G-proteins in Flow 9000 
cells. 
G-protein; Muscarinic receptor; Pertussis toxin; Inositol phosphate; cyclic AMP; (Flow 9000 cell) 
1. INTRODUCTION 
Activation of muscarinic cholinergic receptors 
leads to several distinct intracellular biochemical 
changes. These include changes in intracellular 
cyclic AMP (CAMP) and cyclic GMP (cGMP) con- 
tent, calcium mobilization, and increased 
breakdown of inositol phospholipid [ 11. Recent 
evidence has suggested that changes in intracellular 
calcium and cGMP levels may be secondary to in- 
creased hydrolysis of polyphosphoinositides (PI). 
Indeed, inositol 1,4,5-trisphosphate (1,4,5-IPs) has 
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been shown to release intracellularly sequestered 
calcium from a non-mitochondrial store, 
presumably endoplasmic reticulum [2]. Moreover, 
alteration of guanylate cyclase-mediated cGMP 
production may be related to increased in- 
tracellular calcium levels [3]. 
It is now generally accepted that a family of 
guanine nucleotide-binding proteins (G-proteins) is 
involved in the coupling of a variety of receptors to 
their second messenger-generating systems in- 
cluding adenylate cyclase and the PI-hydrolysing 
enzyme, phosphoinositidase C (PIC) [4]. While it 
is generally accepted that there are two G-proteins 
(G, and Gi) responsible for the coupling of 
stimulatory and inhibitory receptors to the activa- 
tion and inhibition of adenylate cyclase, the identi- 
ty of the G-protein involved in receptor-PIC 
coupling is still uncertain. Recent evidence has im- 
plicated that there are at least two different G- 
proteins participated in receptor-linked PI 
metabolism [5]. These G-proteins are classified by 
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their different susceptibilities to pertussis toxin. 
The first one is a substrate of neither pertussis tox- 
in nor cholera toxin and is present in a great variety 
of tissues [6]. The p21 G-protein encoded by ras 
oncogenes is a candidate of this category [7]. On 
the other hand, in other cell types such as mast 
cells, neutrophils and neuroblastoma cells, the G- 
protein responsible for coupling receptors to PIC 
is pertussis toxin-sensitive and therefore can be 
either Gi, G, (G-protein first identified in bovine 
brain but has no known function [8]) or a Gi/G,- 
like protein [9, lo]. We have been able to show that 
muscarinic agonists interact with both adenylate 
cyclase and PI metabolism in Flow 9000 cells and 
in the present study we have attempted to identify 
the G-protein(s) that couple these two signalling 
pathways. 
2. MATERIALS AND METHODS 
Flow 9000 cells (passsage 17-26) were purchased 
from Flow Laboratories (Herts). Cells were 
cultured in Ham’s FlO medium supplemented with 
sera and antibiotics [ 111. Agonist-induced total 
[3H]inositol phosphate ([3H]IP) accumulation in 
the presence of 10 mM LiCl was used as an index 
of PI turnover. Methods for [3H]inositol prelabel- 
ling and agonist stimulation of the cells as well as 
extraction and quantification of t3H]IP were as 
described in [ll]. Pertussis toxin was routinely 
added only after the cells had been labelled with 
[3H]inositol to isotopic equilibrium (48 h) for 24 h. 
For CAMP determination, cells were incubated 
with different drugs in Krebs-Ringer bicarbonate 
buffer (supplemented with glucose) for IS- 
30 min. Reaction was terminated by aspirating the 
incubation medium followed by adding 1 ml ice- 
cold 6% trichloroacetic acid. Cells were then 
scraped from cultured wells and were then ex- 
tracted with 2 vols water-saturated ether solution 
(three times) to remove the acid. CAMP concentra- 
tions were determined by radioimmunoassay using 
a 1251-cAMP-RIA kit obtained from New England 
Nuclear. Carbachol, acetylcholine hydrochloride, 
prostaglandin Ez (PGE2) and isoprenaline were ob- 
tained from Sigma. GTP[S] was purchased from 
Calbiochem. Pertussis toxin was obtained from 
Lists Biologicals (Campbell, CA). Cell culture 
medium, sera and antibiotics were purchased from 
156 
either Gibco or Flow Laboratories. All other 
chemicals were from Fisons. 
All experiments, unless otherwise stated, have 
been performed at least three times. Results 
presented are means -t SE of three or more ex- 
periments. Statistical analyses were conducted by 
Student’s t-test. 
3. RESULTS AND DISCUSSION 
Initial experiments established that, even in the 
absence of any phosphodiesterase inhibitor, 
isoprenaline or PGE2 both significantly increased 
CAMP formation in intact Flow 9000 cells (fig.1). 
Propranolol (10 nM), but not phentolamine 
(10 nM), completely blocked the stimulatory ac- 
tion of isoprenaline on CAMP formation in- 
dicating that the response of isoprenaline was 
mediated via ,&-adrenergic receptors (not shown). 
Carbachol (O.l-100pM) had no effect on basal 
CAMP level (fig.1). However, it was able to inhibit 
the increase in CAMP levels elicited by either 
isoprenaline or PGE2 (fig.2). Carbachol (1 mM) 
caused 65 and 75% inhibition of the isoprenaline- 
and PGEz-mediated responses, respectively. The 
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Fig.1. Dose-dependent effects of (0) isoprenaline, (0) 
PGEz and (A) carbachol on CAMP production in Flow 
9000 cells. Flow 9000 cells were incubated with different 
agonists of various concentrations for 15 min. The 
reaction was terminated and CAMP extracted and 
quantified as described in the text. Results presented ar,e 
means of 4 independent experiments in triplicate. SE is 
within 10% in each data point. 
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Fig.2. Effects of pertussis toxin pretreatment on 
carbachol inhibition of agonist-induced CAMP 
formation. Control (open bar) and pertussis toxin- 
pretreated (hatched bar) cells were incubated with 
carbachol (CAR, 1 mM) and/or isoprenaline (ISO, 
1 ,uM) or PGEz (40pM) for 30 min. Data represent 
means f SE of 3 separate experiments in duplicate. 
* P C 0.01 vs agonist stimulation in control cells. 
** P < 0.02 vs carbachol plus isoprenaline or PGEz in 
control cells. 
inhibitory action of carbachol was completely 
blocked by atropine (1 FM). 
Pretreatment of Flow 9000 cells with pertussis 
toxin (50,~g/ml, 24 h) affected neither basal nor 
agonist-stimulated CAMP levels. However, per- 
tussis toxin treatment significantly reduced the car- 
bachol inhibition of both isoprenaline and PGEz 
stimulation of CAMP formation (fig.2). This is in 
accord with an action on the inhibitory G-protein 
by pertussis toxin. Pertussis toxin is known to 
ADP-ribosylate the a-subunit of G-protein and by 
doing so prevents the activation of Gi by GTP [ 121. 
Concomitantly, the coupling of hormone receptors 
to Gi is also interrupted [ 131. 
Recently, we have shown that in [3H]inositol- 
prelabelled Flow 9000 cells, muscarinic agonists 
stimulate a rapid and transient increase in the for- 
mation of inositol phosphates [14]. When these 
cells were permeabilized by saponin treatment, 
non-hydrolysable GTP analogues (GTP[S] and 
GppNHp) were able to activate inositol phosphate 
production in a time- and dose-dependent manner 
[15]. Moreover, these GTP analogues ignificantly 
potentiated the responses of cholecystokinin oc- 
tapeptide and muscarinic agonists on PI hydrolysis 
[ 151. These data indicate that receptor-mediated PI
turnover is mediated via a G-protein in Flow 9000 
cells. In the present study, pretreatment of both in- 
tact and saponin-permeabilized [3H]inositol- 
labelled Flow 9000 cells with pertussis toxin (under 
conditions enough to modify the function of Gi) 
had no effect on either muscarinic agonists or 
GTP[S] stimulation of [3H]IP accumulation (table 
1). These results imply that the G-protein involved 
in the coupling of the muscarinic receptor to PIC 
is not a substrate of pertussis toxin. In other 
systems uch as cardiac myocytes and astrocytoma 
cells, a similar observation has been made in that 
the G-protein coupling to PI metabolism is not 
pertussis toxin-sensitive [16,171. 
In conclusion, this study shows that activation 
of muscarinic receptors is linked to both inhibition 
of adenylate cyclase activity and stimulation of PI 
hydrolysis in human embryonic pituitary clonal 
cells Flow 9000. Moreover, these two muscarinic 
Table 1 
Effects of pertussis toxin pretreatment on PI hydrolysis 
in Flow 9000 cells 
[3H]IP (dpm/106 cells) 
Control Pertussis toxin- 
treated 
Intact cells 
Basal 7440 * 593 6363 +- 882 
Carbachol (25 FM) 32550 k 3906 33921 +- 1696 
Acetylcholine 
(25 PM) 52749 -t 2109 49106 + 3240 
Saponin-permeabilized cells 
Basal 5857 f 351 5996 + 479 
GTP[S] (100 PM) 10659 + 426 10573 2 539 
[‘HlInositol-labelled Flow 9000 cells were pretreated 
with pertussis toxin (50pg/ml) or an equal amount of 
culture medium for 24 h. Cells were then washed 
thoroughly and then divided into two slots. The first slot 
of cells (intact) was challenged with muscarinic agonists 
for 30 min. The second slot was treated with saponin 
(50pg/ml) for 15 min and subsequently exposed to 
GTP[S] for 30 min. Total [3H]IP were extracted as 
described in section 2. Data are means + SE of 5 
separate experiments 
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receptor-mediated second messenger pathways can 
be distinguished by pertussis toxin. Experiments 
are in progress to determine whether one 
homogeneous class of muscarinic receptors or dif- 
ferent receptor subtypes [ 181 are involved in the ac- 
tivation of these signalling mechanisms. 
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